Skip to content
Storytelling Co – Lifestyle
Author:
iBio, Inc.
iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
November 10, 2026
iBio to Participate in Upcoming Investor Conferences
November 2, 2026
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
October 13, 2026
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
September 1, 2026
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
August 28, 2026
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
August 4, 2026
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
July 1, 2026
iBio to Participate in Upcoming Healthcare Investor Conferences
June 2, 2026
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
June 2, 2026